Literature DB >> 12618251

The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study.

.   

Abstract

We investigated the effects of ethinylestradiol dose (50, 30 and 20 microg) and progestogen type [desogestrel (DSG), gestodene (GSD), levonorgestrel (LNG) and norgestimate (NGM)] in oral contraceptives on 24 hemostatic variables. In a multicenter, randomized, comparative study, 707 healthy, nonsmoking, nulliparous women were treated for six cycles with one of the seven monophasic oral contraceptives tested. Significantly greater increases in prothrombin fragment 1+2 and factor VII (activity and antigen), were found in the DSG, NGM and GSD groups compared to the LNG group. Similarly, significantly lower levels of protein S (free and total) and increased APC-sr (endogenous thrombin potential based) were found in the same groups compared with the LNG group. In addition, the estradiol dose (50 vs. 30 microg) significantly influenced these parameters. All changes were within the normal range and have not been associated with an increased risk of venous thromboembolic event (VTE). However, raised levels of these variables are associated with prothrombotic states such as pregnancy. The significance of the haemostatic changes found in this study in relation to VTE risk remains to be determined, but results of this study probably cannot explain the differences in risk of VTE between OCs containing different progestogens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12618251     DOI: 10.1016/s0010-7824(02)00476-6

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  9 in total

1.  Endogenous thrombin potential changes during the first cycle of oral contraceptive use.

Authors:  Carolyn L Westhoff; Malcolm C Pike; Serge Cremers; Andrew Eisenberger; Stella Thomassen; Jan Rosing
Journal:  Contraception       Date:  2017-01-11       Impact factor: 3.375

Review 2.  Introduction to haemostasis from a pharmacodynamic perspective.

Authors:  Cornelis Kluft; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

3.  Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill.

Authors:  Maurizio Guida; Giuseppe Bifulco; Attilio Di Spiezio Sardo; Mariamaddalena Scala; Loredana Maria Sosa Fernandez; Carmine Nappi
Journal:  Int J Womens Health       Date:  2010-08-24

4.  Clotting factor changes during the first cycle of oral contraceptive use.

Authors:  Carolyn L Westhoff; Andrew Eisenberger; Rosalind Tang; Serge Cremers; Lisa V Grossman; Malcolm C Pike
Journal:  Contraception       Date:  2015-10-09       Impact factor: 3.375

5.  Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism.

Authors:  Ulla M Ågren; Marjatta Anttila; Kristiina Mäenpää-Liukko; Maija-Liisa Rantala; Hilkka Rautiainen; Werner F Sommer; Ellen Mommers
Journal:  Eur J Contracept Reprod Health Care       Date:  2011-12       Impact factor: 1.848

6.  Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study.

Authors:  Heiko Rühl; Lars Schröder; Jens Müller; Shorena Sukhitashvili; Julia Welz; Walther C Kuhn; Johannes Oldenburg; Christian Rudlowski; Bernd Pötzsch
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

7.  Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women.

Authors:  Rossella E Nappi; Anna Maria Paoletti; Annibale Volpe; Luca Chiovato; Brandon Howard; Herman Weiss; Nancy Ricciotti
Journal:  Eur J Contracept Reprod Health Care       Date:  2014-06-13       Impact factor: 1.848

8.  Clinical and laboratory manifestations of the prothrombin gene mutation in women of reproductive age.

Authors:  A P Momot; M G Nikolaeva; N N Yasafova; M S Zainulina; K A Momot; I A Taranenko
Journal:  J Blood Med       Date:  2019-08-02

9.  Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: Normal values and variability.

Authors:  Sara Calzavarini; Justine Brodard; Claudia Quarroz; Livia Maire; Raphael Nützi; Jovana Jankovic; Laura C Rotondo; Evelyne Giabbani; Georg Martin Fiedler; Michael Nagler; Anne Angelillo-Scherrer
Journal:  Res Pract Thromb Haemost       Date:  2019-07-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.